Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans-Peter Schmid

Showing results (1-10 of 158) with videos related to

Pageof 16
Sort By:
European Urology|April 11, 2007
Re: Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase 1 clinical trialHans-Peter Schmid
Urology|October 19, 2005
Novel use of fine needle aspiration of seminal vesicles for sperm retrieval in infertile menDominik Boehlen, Hans-Peter Schmid
Urology|December 8, 2009
Re: Hellstrom WJG, et al.: Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia (BPH) and BPH treatment. (Urology 2009;74:15-21)Hans-Peter Schmid, Dominik Böhlen
European Urology|April 2, 2017
Re: Clinicopathological Features and Prognostic Value of Incidental Prostatic Adenocarcinoma in Radical Cystoprostatectomy Specimens: A Systematic Review and Meta-analysis of 13 140 PatientsDominik Abt, Hans-Peter Schmid
Praxis|October 4, 2013
[Urination disorders in the man: differential diagnoses and therapy of benign prostate syndrome]Daniel Meyer, Hans-Peter Schmid
Urological Research|June 28, 2002
The rise and fall of PSA: clinical implications of prostate specific antigen kineticsAxel Semjonow, Hans-Peter Schmid
European Urology|December 22, 2011
Words of wisdom. Re: Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastasesHans-Peter Schmid, Robert Theiler
Translational Andrology and Urology|January 28, 2016
Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumabJohannes M Wolff, Hans-Peter Schmid
European Urology|December 10, 2009
Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerHans-Peter Schmid, Daniel S Engeler
Praxis|March 17, 2016
[Problems with Ureteral Stents – a Never-Ending Story]Patrick Betschart, Hans-Peter Schmid, Dominik Abt
Pageof 16

Showing results (1-10 of 158) with videos related to

Sort By:
Pageof 16
European Urology|April 11, 2007
Re: Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase 1 clinical trialHans-Peter Schmid
Urology|October 19, 2005
Novel use of fine needle aspiration of seminal vesicles for sperm retrieval in infertile menDominik Boehlen, Hans-Peter Schmid
Urology|December 8, 2009
Re: Hellstrom WJG, et al.: Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia (BPH) and BPH treatment. (Urology 2009;74:15-21)Hans-Peter Schmid, Dominik Böhlen
European Urology|April 2, 2017
Re: Clinicopathological Features and Prognostic Value of Incidental Prostatic Adenocarcinoma in Radical Cystoprostatectomy Specimens: A Systematic Review and Meta-analysis of 13 140 PatientsDominik Abt, Hans-Peter Schmid
Praxis|October 4, 2013
[Urination disorders in the man: differential diagnoses and therapy of benign prostate syndrome]Daniel Meyer, Hans-Peter Schmid
Urological Research|June 28, 2002
The rise and fall of PSA: clinical implications of prostate specific antigen kineticsAxel Semjonow, Hans-Peter Schmid
European Urology|December 22, 2011
Words of wisdom. Re: Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastasesHans-Peter Schmid, Robert Theiler
Translational Andrology and Urology|January 28, 2016
Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumabJohannes M Wolff, Hans-Peter Schmid
European Urology|December 10, 2009
Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerHans-Peter Schmid, Daniel S Engeler
Praxis|March 17, 2016
[Problems with Ureteral Stents – a Never-Ending Story]Patrick Betschart, Hans-Peter Schmid, Dominik Abt
Pageof 16